

## **LIDDS receives patent approval in Europe**

---

**The European patent office has approved LIDDS' patent related to devices and methods of injection. The patent is now approved in all major markets and provides protection for all drug formulations based on the NanoZolid® technology.**

The patent describes devices and methods for the reconstitution and administration of Liproca® Depot and other NanoZolid® formulations, involving the dispersion of nanoparticles to injectable suspensions for administration as local drug delivery depots.

This patent has thereby been approved in all major markets, including North America, Asia and Europe.

The approval concerns the European patent application with application number EP09815647 and the title "Injector Device".

**For more information, please contact:**

Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, [monica.wallter@liddspharma.com](mailto:monica.wallter@liddspharma.com)

LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 5 June 2018 at 14:15 CET.

**About LIDDS**

LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company's most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. Redeye AB is a certified adviser to LIDDS. For more information, go to [www.liddspharma.com](http://www.liddspharma.com).